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Sarcoidosis is characterized by the presence of 
noncaseating granulomas in a variety of organs, 
most commonly the lung. CD4+ and CD8+ 
T lymphocytes (1), as well as a few B lympho-
cytes, form a characteristic ring at granuloma 
periphery. Most granuloma-associated lym-
phocytes have a Th1 phenotype (2). Th1 cells 
secrete cytokines such as IL-2 and IFN-γ and 
play a central role in the control of the cel-
lular immune response. Mechanisms underly-
ing formation, maintenance, and spontaneous 
resolution of sarcoid granulomas are poorly 
understood (3, 4).
From a general standpoint, one could say 
that sarcoidosis represents an unresolved immu-
nological paradox: aff  ected organs are the stag-
ing ground for an intense immune response, yet 
at the same time, a state of anergy is established 
as indicated by suppression of immune response 
to tuberculin in sarcoidosis patients (5).
Regulatory cells, of which at least two types 
can be distinguished, are capable of   inhibiting 
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diverse immunopathologic phenomena by con-
trolling the proliferation of CD4+ and CD8+ 
T lymphocytes in vivo (6, 7). The fi  rst type 
regulates immune responses via secretion of 
cytokines and corresponds to IL-10–produc-
ing Tr1 cells (8, 9) and TGF-β–producing Th3 
cells (10). The second type of regulatory T cell 
is the naturally occuring, or innate, regu  latory 
T cell (T reg cell). The latter mediates sup-
pression through mechanisms dependent on 
cell contact and is characterized by constitutive 
expression of CD25 (6). Naturally occurring T 
reg cells have also been described in humans 
(11–15), where they are mainly confi  ned to the 
CD25bright subset of CD4+ cells (16). The po-
tential role of T reg cells in human disease is 
currently the focus of intensive research eff  orts 
(17). It is proposed that modulation of either 
the number or function of T reg cells could 
prove benefi  cial in the treatment of autoimmu-
nity and cancer (18–20).
We report here that sarcoidosis is charac-
terized by expansion of the innate T reg cell 
subset and that purifi  ed T reg cells effi   ciently 
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Sarcoidosis is characterized by extensive local infl  ammation (granuloma, cytokine secretion) 
associated with anergy (poor response to antigens in vitro and in vivo). We postulated that 
this paradoxical situation would correspond to a disequilibrium between effector and 
regulatory T lymphocytes (T reg cells). We show that CD4+CD25brightFoxP3+ cells accumu-
late at the periphery of sarcoid granulomas, in bronchoalveolar lavage fl  uid, and in periph-
eral blood of patients with active disease. These cells exhibited powerful antiproliferative 
activity, yet did not completely inhibit TNF-𝗂 production. Sarcoidosis is therefore associ-
ated with a global T reg cell subset amplifi  cation whose activity would be insuffi  cient to 
control local infl  ammation. At the same time, peripheral T reg cells exert powerful antipro-
liferative activity that may account for the state of anergy. Altogether, these fi  ndings 
advance our conceptual understanding of immune regulation in a way that resolves the 
immune paradox of sarcoidosis and permit us to envisage a profound clinical impact of 
T reg cell manipulation on immunity.
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suppress naive T cell proliferation, but are unable to totally 
suppress TNF-α secretion.
RESULTS
Defi  nition of T reg cells
The percentage of CD4+ lymphocytes expressing very high 
levels of CD25 was initially determined using cytofl  uoromet-
ric analysis. The forkhead/winged helix transcription factor 
FoxP3 is crucial to the development and function of T reg 
cells (21–23) and so far considered the best marker available 
to identify naturally occurring T reg cells. Using real-time 
PCR, we confi  rmed that only CD4+CD25bright cells, as de-
fi  ned according to our gating strategy (Fig. 1 a), express high 
levels of FoxP3 among CD4+ T cells (Fig. 1 b). We also used 
a single cell PCR approach to calculate precisely the fraction 
of FoxP3+ cells present among sorted cells. Although very 
few CD4+CD25− cells expressed FoxP3 (0.7%), we deter-
mined by this approach that, on average, 86.5% of sorted 
CD4+CD25bright cells were Foxp3+ (Fig. 1 d). Furthermore, 
CD4+CD25bright T cells present other typical features of nat-
urally occuring T reg cells such as intracellular expression 
of CTLA-4 (24, 25) and cell surface CCR4 expression (19) 
(Fig. 2 a). More importantly, these cells are the only CD4+ 
population that exerts strong dose-dependent inhibition on 
CD4+CD25− T cell proliferation (16) (Fig. 1 c). These com-
bined phenotypic and functional fi  ndings allow us to defi  ne 
the CD4+CD25bright cells enumerated herein as T reg cells.
High levels of blood and BALF CD4+CD25bright T cells 
in active sarcoidosis
We compared the percentage of CD25bright cells among circu-
lating CD4+ T cells in patients and controls (Fig. 2 a, represen-
tative staining patterns). As shown in Fig. 3 a, signifi  cant 
increase in the mean value for patients with active sarcoidosis 
is evidenced when this group is compared with healthy con-
trols or to inactive patients (5.05 ± 5.33%, n = 29 vs. 1.32 ± 
0.39%, n = 55, P < 0.0001; and 1.18 ± 0.81%, n = 18, P = 
0.001, respectively). No signifi  cant diff  erence was observed 
between inactive sarcoidosis and healthy controls (P = 0.25). 
We noted a modest but nevertheless signifi  cant decrease in the 
mean percentage of circulating CD4+CD25bright T cells in pa-
tients presenting with active tuberculosis compared with 
healthy controls (0.89 ± 0.41%, n = 13, P = 0.0016). Finally, 
CD4+CD25bright T cells are also abundant in sarcoidosis-in-
volved organs. A signifi  cant increase in the mean percentage of 
BALF CD4+CD25bright T cells is noted in active sarcoidosis as 
compared with diseases that mimic sarcoidosis (7.01 ± 3.96%, 
n = 19, vs. 1.18 ± 0.85%, n = 24, P < 0.0001). On one oc-
casion, we were able to extract lymphocytes from a sarcoid 
skin biopsy and determine that 7.8% of the skin CD4+ T cells 
were CD25bright (Fig. 2 a).
BALF CD4+CD25bright T cells overexpress CXCR3
In an attempt to identify a potential mechanism that would 
explain why many CD4+CD25bright T cells are found in the 
lung, whereas others recirculate to the periphery, we stud-
ied their chemokine receptor expression. All CD4+CD25bright 
T cells express CCR4 (Fig. 2 a), but only a minority of 
them express CXCR3 in control blood (Fig. 2 b). In con-
trast, we found that in sarcoidosis patients, all BALF 
CD4+CD25bright cells express high levels of CXCR3, 
whereas only a low level display of this receptor is found on 
the corresponding blood subset. The CD4+CD25bright T cell 
expression pattern of other chemokine receptors (CCR1 to 
CCR9, CXCR4, CXCR6, and CX3CR1) was also studied 
(26), but no clear diff  erence between patients and control 
was observed (Fig. 2 b).
CD4+CD25bright T cells from a sarcoidosis patient express 
a polyclonal TCR repertoire
To address the question of whether CD4+CD25bright T cell 
numbers are increased during active sarcoidosis as a result 
of oligoclonal expansion, we investigated the T cell reper-
toire usage of sorted CD4+CD25bright T cells. As described 
previously (27, 28), we chose to study nine BV families that 
span >50% of the TCRBV repertoire expressed in healthy 
individuals (29, 30). We used the Immunoscope tech-
nique (31), which is based on the analysis of TCR CDR3 
length polymorphism to assess the clonal composition of 
the CD4+CD25bright T cell subset. 5 × 105 of these cells, 
as well as a corresponding number of CD4+CD25− T cells, 
were purifi  ed from a lymph node obtained from one pa-
tient with active sarcoidosis. It was verifi  ed that the sorted 
CD4+CD25bright T cells used for repertoire analysis were in-
deed immunosuppressive (Fig. 2 a). Immunoscope analysis of 
cells isolated from one patient shows (Fig. 4) that both subsets 
are similarly diverse and also display similar TCRB CDR3 
size distributions.
Contraction of the CD4+CD25bright subset upon 
resolution of sarcoidosis
Because we observed that active sarcoidosis is characterized 
by the expansion of CD4+CD25bright T cells, we next ques-
tioned whether this subset size would vary within the same 
individual in relation to disease activity. In the 11 individu-
als tested longitudinally, there was a marked contraction of 
the initially expanded CD4+CD25bright circulating subset 
that returned to normal levels upon resolution of disease 
activity (5.2 ± 4.7% vs. 1.2 ± 0.4%, P = 0.02 using the 
Wilcoxon Signed-Rank test; Fig. 2). Amplifi  cation of the 
CD4+CD25bright T cell subset is therefore clearly related to 
the disease process.
CD4+ FoxP3+ cells accumulate in the periphery 
of noncaseating granulomas
We subsequently sought to visualize where T reg cells were 
localized in aff  ected organs using bicolor microscopic analysis. 
As shown in Fig. 5, T reg cells identifi  ed as CD4+FoxP3+ cells 
accumulate in the granuloma periphery. These cells are also 
clearly more abundant in sarcoidosis-involved lymph nodes than 
in normal lymphoid tissue from control subjects (6.48 ± 2.12% 
of CD4+ cells, n = 10 vs. 1.67 ± 0.67%, n = 2).JEM VOL. 203, February 20, 2006   361
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CD4+CD25bright T cells from active patients suppress 
T cell proliferation
Phenotypic characterization of CD4+CD25bright cells as being 
also CCR4+CTLA-4+ is not suffi   cient to defi  ne them as im-
munosuppressive T reg cells. We therefore tested whether 
the CD4+CD25bright subset found expanded during active 
sarcoidosis is functionally active by purifying and testing it ex 
vivo. As expected, CD4+CD25− T cells from sarcoidosis pa-
tients have a reduced proliferation capacity as compared with 
healthy controls (29,700 ± 24,130 cpm, n = 18 vs. 62,300 ± 
20,200 cpm, n = 19, P = 0.0005). However, irrespective 
of their tissue of origin (blood, BALF, or lymph node), 
CD4+CD25bright T cells from sarcoidosis patients inhibit T 
cell proliferation as effi   ciently as control CD4+CD25bright T 
cells (Fig. 6 a).
Sarcoidosis T reg cells abolish IL-2 but not IFN-𝗄 or TNF-𝗂 
secretion by autologous and allogeneic cells
It is believed that TNF-α could play a central role in sarcoid-
osis physiopathology (3, 4). The eff  ect of patients isolated T 
reg cells on cytokine production was therefore studied. Cell 
cultures of each of nine patients and nine controls were ana-
lyzed three times over a period of 5 d (Fig. 6 b). In the control 
branch of the study, T reg cells completely inhibited TNF-α 
and IFN-γ secretion as measured on day 5 after stimulation 
(partial inhibition on day 3), whereas in the experimental arm, 
a clear residual cytokine secretion was apparent on day 5. 
These data are summarized in Fig. 6 c. Intriguingly, patients’ 
T reg cells completely inhibit IL-2 production (mean residual 
secretion 4.21 ± 2.57%, n = 18 vs. 4.23 ± 2.90%, n=19, in 
controls), but not that of IFN-γ (19.02 ± 12.37% vs. 4.07 ± 
2.91%) or TNF-α (27.23 ± 15.29% vs. 2.45 ± 2.7%). In 
comparison, control T reg cells inhibit the secretion of all 
three cytokines.
We then sought to determine if the expanded 
CD4+CD25bright subset could itself represent a notable source 
of TNF-α in patients suff  ering from sarcoidosis. In fi  ve pa-
tients and four controls, we obtained enough CD4+CD25bright 
cells to study cytokine secretion in an isolated manner. As 
shown, CD4+CD25bright cells contribute only slightly to the 
residual level of TNF-α secretion observed in the patient 
Figure 1.  Isolation and characterization of human natural T reg 
cells. (a) Red background fl  uorescence upper level (x axis) is used to 
defi  ne the CD4+CD25− sorting gate (top left). The CD4+CD25+++ 
(CD25bright) gate was adjusted to contain CD4+ T cells that express CD25 
more brightly than CD4−CD25+ cells (top right). CD4+CD25+ cells are 
mainly CD4high, but a tiny fraction is also CD4low. CD4 fl  uorescence levels 
were therefore used to defi  ne CD4+CD25+ and CD4+CD25++ subsets as 
shown (bottom). Analysis was restricted to lymphocytes defined 
according to morphologic parameters. (b) Only CD25bright cells express 
high levels of FoxP3 among CD4+ T cells. Quantifi  cation of relative FoxP3 
mRNA levels in CD4+ T cell subsets were sorted as indicated. cDNA sam-
ples were subjected to real-time quantitative PCR analyses using primers 
and an internal fl  uorescent probe specifi  c for FoxP3 or HPRT. (c) CD25bright 
cells strongly inhibit the proliferation of autologous CD4+CD25− cells. 
1 representative healthy control out of 10 was analyzed for natural T reg 
cell activity. (d) Detection of FoxP3 transcripts in single cells sorted ac-
cording to the aforementioned defi  ned parameters. One lane corresponds 
to one cell. Multiplex PCR was performed on 190 CD4+CD25bright cells and 
282 CD4+CD25− cells to detect FoxP3 and CD3δ simultaneously (chosen 
as a lymphocyte house-keeping gene). As shown, six out of seven repre-
sentative CD4+CD25bright cells are also FoxP3+ (164 cells out of 190, 
86.3%). Only two CD4+CD25− cells were FoxP3+ (0.7%).362   T REG CELL SUBSET EXPANSION IN SARCOIDOSIS | Miyara et al.
Figure 2.  Phenotype and proportion of CD4+CD25bright T cells in 
patients and controls. (a) CD4+CD25bright T cells are abundant in blood, 
BALF, lymph nodes, and skin of patients with active sarcoidosis. Represen-
tative cytofl  uorometric analysis of (from left to right) healthy donor 
PBMCs, active sarcoidosis (AS) PBMCs, AS BALF lymphocytes, AS lympho-
cytes isolated from a lymph node (LN), and AS skin lymphocytes is shown. 
The percentage of CD4+ T cells expressing very high levels of CD25 (CD-
25bright) is indicated in each case. Gates used to count and sort 
CD4+CD25bright cells are shown. CD4+CD25− (unshaded histograms) and 
CD4+CD25bright cells (shaded histograms) were simultaneously analyzed 
for their expression of membrane CCR4 and intracellular CTLA-4 (iCTLA-4). 
(b) Comparative expression of CXCR3 on BALF and blood CD4+CD25bright 
cells. CD4+CD25bright cells were analyzed by fl  ow cytometry for their ex-
pression of membrane CXCR3 in one patient with active sarcoidosis and 
in one healthy control (left). Results of one representative experiment out 
of fi  ve are presented. Expression of other indicated chemokine receptors 
in a representative control subject and in one AS patient is shown. Flow 
cytometry analysis of CD4+CD25bright and CD4+CD25− gated lymphocytes 
is presented. Results of one representative experiment out of two are 
presented. (c) Contraction of the CD4+CD25bright circulating subset upon 
resolution of sarcoidosis. One representative longitudinal cytofl  uorometric 
analysis (left and middle). Longitudinal monitoring of CD4+CD25bright T 
cells in 11 patients with resolutive sarcoidosis (right). Percentage of pe-
ripheral blood CD4+CD25bright cells was initially measured when sarcoid-
osis was active and after resolution (mean time interval between two 
measures: 5 mo ± 2.5). The horizontal dashed line represent the average 
percentage of CD4+CD25bright T cells in healthy controls (n = 55). 
Comparisons were made using the Wilcoxon Signed Rank test.JEM VOL. 203, February 20, 2006   363
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group after 5 d of stimulation (Fig. 6 b). Further control ex-
periments confi  rmed that early production (day 1) of TNF-α 
is of accessory cell (AC) origin, whereas the bulk of TNF-α 
released during the course of activation is produced by 
CD25− T cells (Fig. 6 d). As shown, only the latter source of 
TNF-α is sensitive to T reg–mediated suppression.
We then examined whether this confi  rmed partial loss of 
regulatory function on cytokine secretion was the result of a 
decrease in T reg cell activity or to a resistance of the patients’ 
CD4+CD25− cells to inhibition. To address this issue, “criss-
cross” experiments were performed. T reg cells from patients 
were tested on healthy donors’ responder cells, and vice versa 
(Fig. 6 c). T reg cells from patients do not completely block 
cytokine secretion from either patients or healthy controls. 
However, residual amounts of TNF-α are also detected in the 
supernatants of sarcoidosis CD4+CD25− cells stimulated in 
the presence of control T reg cells.
The aforementioned results were obtained using low-dose 
anti-CD3 (16), and allogeneic ACs as stimulus according to 
previous defi  ned protocols (12–14, 32, 33). To verify that the 
persistence of TNF-α and IFN-γ would not in fact be second-
ary to strong allogeneic responses, we repeated the functional 
analyses of T reg cells using only autologous ACs and anti-
CD3 (0.5 μg/ml). Under these conditions, TNF-α and IFN-γ 
production are not totally suppressed by sarcoidosis T reg cells 
(n = 4) compared with controls (n = 5, P < 0.02, Fig. 6 d). 
Therefore, the incomplete control of TNF-α and IFN-γ pro-
duction is not only observed in the context of strong 
  allogeneic responses.
Most IFN-𝗄/TNF-𝗂–secreting cells do not produce IL-2
It follows from our results that (a) TNF-α and IFN-γ pro-
duction and (b) IL-2 production would be diff  erentially af-
fected by the presence of T reg cells. We postulated that 
this could be partially explained by the fact that TNF-α 
and IFN-γ are usually produced by cells that no longer (or 
never) made IL-2. To address that issue, we used four-color 
cytometry to monitor IL-2, TNF-α, and IFN-γ at a single 
cell level in three patients and fi  ve controls after a short-term 
in vitro stimulation (Fig. 7). We show that IFN-γ and IL-2 
production are almost mutually exclusive. Although some 
TNF-α–producing CD4+ cells can secrete IL-2, a subset of 
CD4+IL2−TNF-α+IFN-γ+ cells can be clearly defi  ned in pa-
tients’ and controls’ blood (Fig. 7). Altogether, we conclude 
on the existence of a defect in regulatory function exerted by 
sarcoidosis T reg cells, as well as a concurrent relative resis-
tance on the part of highly diff  erentiated (TNF-α+, IFN-γ+) 
autologous eff  ector T cells.
D  I  S  C  U  S  S  I  O  N 
It is generally accepted that sarcoidosis is a disorder mediated 
by excessive local helper T lymphocyte activity (1). Until 
now however, it has been diffi   cult to explain why the intense 
infl  ammatory activity observed in sarcoidosis patients is com-
monly accompanied by a state of anergy. It was originally 
proposed that suppressive CD8 T cells could be involved in 
the down-modulation of cellular responses (1). More re-
cently, a high percentage of CD4+CD25bright cells was re-
ported in the blood and BALF of HLA−DR17+ patients with 
Figure 3.  Global CD4+CD25bright amplifi  cation in active sarcoidosis 
patients. (a) The percentage of peripheral blood CD4+CD25bright T cells in 
controls, tuberculosis patients, inactive sarcoidosis patients, and active 
sarcoidosis patients is shown. (b) The percentage of CD4+CD25bright cells 
among alveolar lymphocytes in patients with active sarcoidosis and 
patients with control lung diseases is depicted. The horizontal lines 
represent mean levels for each group. Comparisons were made using 
the nonparametric Mann-Whitney U test.364   T REG CELL SUBSET EXPANSION IN SARCOIDOSIS | Miyara et al.
active disease (34), but the regulatory activity of these cells 
was not demonstrated.
We show here that the T reg population is indeed glob-
ally amplifi  ed in circulating blood and BALF of patients pre-
senting with active sarcoidosis. In vitro, the capacity of these 
cells to strongly inhibit the proliferation and IL-2 secretion of 
CD4+CD25− T lymphocytes contrasts with their inability to 
completely inhibit the secretion of TNF-α (and to a lesser 
extent IFN-γ). The latter observation could be particularly 
relevant as TNF-α plays a key role in granuloma formation 
(35) and because anti-TNF-α drugs have proved useful in the 
treatment of refractory sarcoidosis (36). Because T reg cells 
do not completely block TNF-α secretion, they might only 
partially control granuloma evolution in vivo. A limited ef-
fect of T reg cells on TNF-α secretion has previously been 
reported in patients suff  ering from rheumatoid arthritis (37). 
T reg function was also found impaired in multiple sclerosis 
(38). Given our data, we cannot conclude that T reg cells 
found in sarcoidosis patients have an intrinsic defect. It is 
equally probable that these cells are simply incapable of con-
trolling an abnormally abundant secretion of TNF-α. Our 
analysis of cytokine production at a single cell level (Fig. 7) 
delineates nonoverlapping subsets of CD4+ cells as defi  ned 
according to their cytokine secretion profi  le. In particular, a 
CD4+IL2−IFN-γ+TNF-α+ subset can be clearly defi  ned. 
More work will be necessary to determine whether the later 
subset would be less sensitive to T reg suppression functional-
ity in sarcoidosis patients. In any case, it is possible that phe-
notypically and functionally distinct subsets of CD4+ cells 
would be diff  erentially regulated by T reg cells.
Although unable to totally suppress TNF-α and IFN-γ 
production in sarcoidosis patients, T reg cells exert a profound 
antiproliferative activity and are able to abolish IL-2 secretion 
as expected (mean suppression 95.8 ± 2.6%, Fig. 6 c). T cell 
expansion represents a crucial aspect of memory responses. 
Memory T lymphocytes specifi  c for a given antigen are scarce. 
The latter could have their proliferation eff  ectively suppressed 
when they encounter their recall antigen in lymphoid organs 
harboring an abnormal proportion of T reg cells. We show 
that T reg cells are indeed abundant in aff  ected lymph nodes, 
but are infrequently found in the lymph nodes of healthy con-
trols, lending support to a T reg cell/T memory disequilibrium 
as a possible mechanism of anergy.
We therefore postulate that the aforementioned paradox 
can be solved if one considers that T reg cells tightly control T 
cell homeostasis mainly through the control of T cell expansion 
(39), and that this mechanism is overly eff  ective in sarcoidosis 
patients. Alternatively, the same mechanism would not effi   -
ciently control the infl  ammation of injured tissues.
In active sarcoidosis patients, the chemokine receptor 
CCR4 is preferentially expressed on CD4+CD25bright T reg 
cells irrespective of their tissue of origin. In contrast, CXCR3 
is overexpressed on BALF CD4+CD25bright cells. It was re-
cently demonstrated that the specifi  c recruitment of T reg 
cells in human ovarian tumors is mediated by the secretion of 
the CCR4 ligand CCL22 (macrophage-derived chemokine) 
by tumor cells and microenvironmental macrophages (19). 
However, lung macrophages from sarcoidosis patients do not 
secrete CCL22 (40), whereas they are known to produce 
high levels of the CXCR3 ligand CXCL10 (IFN-γ–induc-
ible 10-kd protein [IP-10]) (41). It is therefore possible that 
it is in response to IP-10 secretion by activated tissue mac-
rophages that CXCR3+ T reg cells are recruited to aff  ected 
organs. Only cells that down-modulate CXCR3 would re-
circulate to the periphery. To explore another potential 
mechanism that would induce T reg migration and   expansion, 
Figure 4.  TCR diversity analysis of sarcoidosis CD4+CD25bright T 
cells. Comparative high resolution TCR BV CDR3 Immunoscope analysis 
of one patient’s CD4+CD25− (left) and CD4+CD25bright T cells (right). Both 
subsets were fl  ow sorted from a lymph node suspension. Nine BV families 
were studied; the BV profi  le presented is indicated in each box. The graphs 
represent the intensity of fl  uorescence in arbitrary units, as a function of 
the CDR3 length, in amino acids. Windows are centered on TCRBV DNA 
run-off products corresponding to transcripts encoding a 10-residue-long 
CDR3 region.JEM VOL. 203, February 20, 2006   365
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Figure 5.  Location of T reg cells within granuloma. (a) FoxP3+ cells 
(red nuclear staining) are also CD4+ (green cytoplasmic and membrane 
staining). The diffuse nonspecifi  c staining of collagen fi  bers in the center 
of the picture corresponds to a granuloma core found in a sarcoidois 
patient’s lymph node (magnifi  cation, 250). Also depicted is a higher mag-
nifi  cation view (650×) of adjacent FoxP3+ and FoxP3− CD4+ cells (insert). 
(b) FoxP3+ T reg cells (red label) encircle granuloma lesions (G) in a pa-
tient’s lymph node. Representative low magnifi  cation (100×) immuno-
histological analysis of 1 lymph node out of 10 analyzed. (c) FoxP3+CD4+ 
T reg cells (250×) are randomly distributed and less abundant in control 
lymph nodes (left, one representative sample out of two) than in lymph 
nodes from sarcoidosis patients (right, 1 sample out of 10). For statistical 
analysis, FoxP3+ cells were enumerated in three independent areas in 
each sample. Comparisons were made using the nonparametric Mann-
Whitney U test.
we also studied the clonal diversity of this subset (Fig. 4). Us-
ing CDR3-length polymorphism analysis (27), we found that 
CD4+CD25bright T reg cells are polyclonal in one sarcoidosis 
patient. It is therefore unlikely that in this case CD4+CD25bright 
expansion would result from direct antigenic stimulation. 
Unfortunately, it was not possible until now to purify enough 
CD4+CD25bright cells from sarcoidosis BALF to perform ad-
ditional reliable repertoire studies. It is known that oligoclo-
nal population of αβ+ CD4+ T cells collect at granulomatous 
sites (42–44) and at Kveim reaction sites (45). Mycobacterial 
catalase-peroxydase was recently identifi  ed as one target 
of the adaptive immune response in sarcoidosis (46), but it 
  remains unknown whether granuloma-associated T cells 
actually include mycobacterial catalase-peroxydase–specifi  c 
T cells. In light of the data presented here, it could be inter-
esting to study the reactivity of sarcoidosis T reg cells against 
mycobacterial antigens. In a fi  rst step, it will be necessary to 
solve the issue of the T reg repertoire diversity at granuloma-
tous sites of infl  ammation.
To our knowledge, there is no clinical situation in which 
a T reg amplifi  cation of such magnitude (up to 21% of CD4+ 
T cells) has been found in the blood of patients. It is possible 
that the observed spontaneous release of IL-2 by lung T lym-
phocytes in active pulmonary sarcoidosis could be one of the 
factors that participate to their amplifi  cation (47). Circulating 
CD4+CD25bright cells were reported elevated during chronic 
graft-versus-host disease (48), but never exceeded 11% of 
CD4+ T cells. Accumulation of T reg cells has also been ob-
served in the joints of rheumatoid arthritis patients (49) and 
in Hodgkin lymphoma–infi  ltrated lymph nodes (50). More 
studies are underway to confi  rm whether the expansion of 
circulating T reg cells is specifi  c enough to distinguish sar-
coidosis from any other granulomatosis. There currently ex-
ists no gold standard to confi  rm the diagnosis of sarcoidosis. 
We will therefore work to determine the peripheral blood or 
BALF T reg cell concentration that supports this diagnosis.
Finally, it is proposed that modulation of either the num-
ber or function of T reg cells could represent a means of con-
trolling autoimmunity or other immunopathologic conditions 
(7, 18). Our data clearly support this assertion, but also indi-
cate that such potential therapies might be, in the long term, 
detrimental to immune surveillance. Indeed, sarcoidosis pa-
tients are predisposed to opportunistic infections (51) and 
cancer (52). It was previously proposed that the increased 
cancer risk would result from chronic infl  ammation and sub-
sequent tissue damage in aff  ected organs (52). In light of the 
data presented here, we propose that a T reg cell/Th1 imbal-
ance could also be evoked to explain why sarcoidosis patients 
have such a predisposition.
MATERIALS AND METHODS
Patients. 47 consecutive adult patients (25 women and 22 men; mean age: 
43 yr; range: 23–65 yr) who had a clinical picture consistent with sarcoidosis 
(3) were recruited for this study. Patients were divided into two groups: pa-
tients with active, newly diagnosed sarcoidosis (n = 29) and patients with inac-
tive disease (n = 18). Patients with active disease were studied before any 
treatment was initiated. Patients with inactive disease were either on low dose 
steroid therapy (<10 mg/day; n = 13) or not treated at all (n = 5). Blood 
samples from 55 age and sex matched healthy donors were obtained from 
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Figure 6.  Sarcoidosis T reg cells suppress T cell proliferation but 
not IFN-𝗄 or TNF-𝗂 secretion. (a) Control and sarcoidosis 
CD4+CD25bright cells strongly inhibit proliferation of autologous 
CD4+CD25− cells. Results are shown of add-back experiments in a rep-
resentative healthy volunteer (out of 19 tested, see panel b) and in a 
representative sarcoidosis patient. CD4+CD25− T cells were fl  ow sorted JEM VOL. 203, February 20, 2006   367
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disease control group consisted of 13 HIV-negative patients (3 women and 10 
men; mean age: 39 yr; range: 19–61 yr) recently diagnosed with active tuber-
culosis. BALF analysis was performed on 19 active sarcoidosis cases and 24 
control cases unrelated to sarcoidosis: nonspecifi  c interstitial pneumonitis 
(n = 4),   pulmonary tuberculosis (n = 2), lymphoma with pulmonary involve-
ment (n = 2), uveitis (n = 14), and pulmonary bacterial infections (n = 2). 
Fresh LN biopsies were obtained from two active sarcoidosis patients and two 
healthy donors undergoing surgery (graft donors). The study was performed 
according to the Helsinki declaration. The study protocol was reviewed and 
approved by the local ethics committee (Comité Consultatif de Protection des 
Personnes dans la Recherche Biomédicale of Pitié-Salpétrière Hospital).
Cytometry. Mononuclear cells isolated from peripheral blood, BALF, and 
LNs were stained with anti-CD4–PerCP, anti-CD25–PE, or anti-CD25-
  allophycocyanin, anti-CCR4–PE mAbs (BD Biosciences), anti-CCR2–PE, 
anti-CCR3–PE, anti-CCR5–PE, anti-CCR6–PE, anti-CCR7–PE, anti-
CCR8–PE, anti-CCR9–PE, anti-CX3CR1–PE anti-CXCR4–PE, anti-
CXCR6–PE and anti-CXCR3–FITC (R&D Systems). Intracellular 
detection of CTLA-4 with anti-CD152–PE was performed on fi  xed and 
permeabilized cells using Cytofi  x/Cytoperm (BD Biosciences). FACSCali-
bur (Becton Dickinson) acquired data were analyzed with WinMDI 2.8 soft-
ware (http://facs.scripps.edu/software.html) on 500,000 events. Cells were 
sorted using a FacsVantage (Becton Dickinson).
Proliferation assay and cytokine detection. Varying numbers of sorted 
CD4+CD25bright T cells were cocultured in supplemented medium (26) with 
2.5 103 autologous CD4+CD25− responder T cells and 2.5 104 allogeneic or 
autologous T cell–depleted PBMCs (irradiated at 5,000 rad) in 96 U-bottom 
well plates coated with 0.5 μg/ml of OKT3 (Orthobiotech). On day 5, 
1 μCi [3H]-thymidine (MP Biomedicals) was added for the fi  nal 16 h of cul-
ture and proliferation was determined on day 6 (Wallac; Perkin-Elmer). IL-2, 
IFN-γ, and TNF-α levels were measured in days 1, 3, and 5 supernatants 
using a cytometric bead array kit (BD Biosciences). Intracellular detection of 
Th1 cytokines was performed on fresh PBMCs stimulated for 24 h with 
5 ng/ml of PMA. 3 μg/ml of brefeldin A and 3 μg/ml of monensin were 
added after the fi  rst 2 h of culture in the presence of PMA (all obtained from 
Sigma-Aldrich). Stimulated cells were permeabilized and stained with anti-
CD4–perCP, anti-IL-2-PE, anti–TNF-α–allophycocyanin, and anti–IFN-
γ–FITC (all obtained from BD Biosciences). None of the patients tested for 
proliferation and cytokine production were on steroids at the time of analysis.
TCRBV analysis. Total RNA was extracted from FACS-sorted cells and 
reverse transcribed using a single-strand synthesis kit (Stratagene). Amplifi  ca-
tion reactions were performed using a BC1/BC2-specifi  c primer (5′-C  G  G-
G  C  T  G  C  T  C  C  T  T  G  A  G  G  G  G  C  T  G  C  G  -3′) and a BV-specifi  c primer (53). In 
brief, 2 μl RT product (corresponding to 2 × 104–105 CD4+CD25bright or 
CD4+CD25− cells) were brought to a fi  nal reaction volume of 50 μl con-
taining 10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, pH 8.3, 20 pmol of 
each oligonucleotide, 0.2 mM of each dNTP, and 2.5 U Taq DNA poly-
merase blocked by the addition of an anti-Taq mAb (Taq Start; CLON-
TECH Laboratories, Inc.). After an initial denaturation step of 3 min at 
95°C, the reactions were subjected to 30 cycles of PCR (94°C for 30 s, 60°C 
for 1 min, 74°C for 1 min), followed by a fi  nal extension step of 5 min at 
74°C. One nested BC oligonucleotide (5′-G  T  G  C  A  C  C  T  C  C  T  T  C  C  C  A  T  T-
C  A  -3′) was used dye-labeled (JOE Fluorophore; Applied Biosystems) in 
runoff   reactions. 2 μL of PCR product was added to 8 μl of a mixture con-
taining 10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, pH 8.3, 0.2 mM 
each dNTP, 0.2 U Taq DNA polymerase, and 0.1 μM JOE Fluorophore–
labeled oligonucleotide. The extension reaction consisted of a 3-min dena-
turation step at 95°C followed by 12 cycles of 30 s at 94°C, 30 s at 60°C, and 
2 min at 72°C. A fi  nal 10-min incubation at 72°C was performed. Runoff   
products were loaded on a 4% acrylamide-4 M urea sequencing gel and run 
on an ABI 377 DNA sequencer (Applied Biosystems). A mixture of dye-la-
beled size standards was also loaded on the sequencing gel to allow the pre-
cise determination of the sizes of the BC-BV runoff   reaction products. The 
sizes and areas of the peaks corresponding to the DNA products were deter-
mined using the Immunoscope software (31). Observed peaks were usually 
separated by three bases and corresponded to in-frame transcripts of TCRs. 
Windows of analysis were centered on expected sizes corresponding to 
TCR transcripts encoding a 10 residue-long CDR3 region.
BV family-specifi  c primers used were as follows: BV1, 5′-C  C  G  C  A  C-
A  A  C  A  G  T  T  C  C  C  T  G  A  C  T  T  G  C  -3′; BV2, 5′-G  G  C  C  A  C  A  T  A  C  G  A  G  C  A  A-
G  G  C  G  T  C  G  A  -3′; BV3, 5′-C  G  C  T  T  C  T  T  C  C  G  G  A  T  T  C  T  G  G  A  G  T  C  C  -3′; 
BV4, 5′-T  T  C  C  C  A  T  C  A  G  C  C  G  C  C  C  A  A  A  C  C  T  A  A  -3′; BV5, 5′-A  G  C  T  C  T-
G  A  G  C  T  G  A  A  T  G  T  G  A  A  C  G  C  C  -3′; BV7, 5′-C  C  T  G  A  A  T  G  C  C  C  C  A  A  C  A-
G  C  T  C  T  C  T  C  -3′; BV8, 5′-C  C  A  T  G  A  T  G  C  G  G  G  G  A  C  T  G  G  A  G  T  T  G  C  -3′; 
BV15, 5′-C  A  G  G  C  A  C  A  G  G  C  T  A  A  A  T  T  C  T  C  C  C  T  G  -3′; and BV16, 5′-G  C-
C  T  G  C  A  G  A  A  C  T  G  G  A  G  G  A  T  T  C  T  G  -3′.
Detection of FoxP3+ T cells. Frozen lymph node tissue obtained from sar-
coidosis patients (n = 10) and controls (n = 2) were stained with polyclonal goat 
anti–human FoxP3 (ab2481; Abcam) and mouse anti–human CD4 (MT310; 
DakoCytomation), followed by FITC-conjugated rat anti–mouse (145–095-
166; Jackson ImmunoResearch Laboratories) and biotinylated rabbit anti–goat 
(E0466, DakoCytomation) followed by cyanine-3–conjugated streptavidin 
(PA43001; GE Healthcare). Fluorescent images of mounted sections were ac-
quired with an epifl  uorescent microscope (Axioplan 2; Carl Zeiss MicroImag-
ing, Inc.) and analyzed with FluoUp image analysis software (Explora Nova).
from blood (n = 18), BAL (n = 3) or lymph node (n = 2) and stimulated 
with anti-CD3 and irradiated allogeneic AC in the presence of different 
numbers of fl  ow sorted CD4+CD25bright autologous T cells (CD25bright/
CD25− ratios are indicated). (b) Time course analysis of cytokine secre-
tion in patients and controls. IL-2, TNF-α, and IFN-γ were measured in 
supernatants from individual wells that were prepared for the in vitro 
suppression assays. In indicated patients and controls, cytokine secretion 
of CD4+CD25bright alone was also studied. Individual analyses are pre-
sented. Mean values on day 5 and at a 1/1 ratio of CD25bright/CD25 
autologous coculture are as follows: IL-2, 1.47 ± 1.80 pg/ml vs. 1.82 ± 
1.53 pg/ml, P = 0.49; TNF-α, 211.9 ± 152.7 pg/ml vs. 183.9 ± 237.4 pg/
ml, P < 0.0001; and IFN-γ 1,530.6 ± 1,782 pg/ml vs. 868.5 ± 1,232 pg/
ml, P = 0.0003 (patients, n = 18 vs. controls, n = 19). (c) Sarcoidosis 
T reg cells strongly inhibit autologous CD4+CD25− proliferation and IL-2 
secretion, but not IFN-γ or TNF-α. In comparison, control T reg cells 
strongly inhibit all three cytokines. Sarcoidosis T reg cells do not com-
pletely block allogeneic secretion of IFN-γ and TNF-α. Note that control 
T reg cells do not either completely block patient’s TNF-α secretion. 
Mean percentage of residual proliferation and corresponding mean per-
centage of residual cytokine secretion of CD4+CD25− cells cocultured 
with autologous or allogeneic fl  ow sorted T reg cells are presented. 
(d) Lack of complete TNF-α and IFN-γ suppression is not related to 
strong allogeneic responses. Add-back experiments presented in a–c 
have been repeated in the absence of allogeneic AC. Blood CD4+CD25− 
T cells were instead stimulated with anti-CD3 (0.5 μg/ml) and irradiated 
autologous AC in the presence or in the absence of CD4+CD25bright T cells 
(CD25bright/CD25− ratios are indicated). Proliferation of AC alone was also 
tested (AC). Indicated cytokines were measured in the culture superna-
tants at indicated times (days). Note that early TNF-α secretion is con-
tributed by AC. One representative experiment in a representative control 
and a representative sarcoidosis patient (top and middle) are shown. 
Results from four independent patients and fi  ve independent controls 
are presented (bottom). Comparisons were made using the nonpara-
metric Mann-Whitney U test.368   T REG CELL SUBSET EXPANSION IN SARCOIDOSIS | Miyara et al.
Real-time FoxP3 PCR. Real-time PCR was performed with a TaqMan 
assay on an ABI 7700 system (Applied Biosystems). Total RNA extracted 
from FACS sorted cells was immediately reverse transcribed in a 50 μL reac-
tion volume (ProSTAR First Strand; Stratagene) according to the manufac-
turer’s instructions. FoxP3 and HPRT-1 Assays-on-Demand gene expression 
probes (Hs 00203958 and 99999909, respectively; Applied Biosystems) were 
used. In each reaction, HPRT-1 was amplifi  ed as a housekeeping gene to 
calculate a standard curve and to correct for variations in target sample quan-
tities. Relative copy numbers were calculated for each sample from the stan-
dard curve after normalization to HPRT-1 by the instrument software.
Single cell RT-PCR. Peripheral blood lymphocytes were stained with 
anti–human CD4-FITC and anti–human CD25-PE (BD Biosciences). 
Single cells were sorted using a FACS Vantage (Becton Dickinson) into 
96-well PCR plates (Abgene, Epsom). Each cell sample was dropped in 
10 μl ice cold reaction buff  er containing 50 mM Tris-HCl, pH 8.3, 75 
mM KCl, 3 mM MgCl2, 0.5 μg oligodT, 0.5 μg random primer, 10 mM 
DNTP, 10 mM DTT, 0.5% vol/vol NP-40, 12 U recombinant RNAsin 
(Promega), 25 U Stratascript RT (Stratagene), and 100 pmol of 3′Fox-
P3cDNA-(5′-A  G  G  A  G  C  C  C  T  T  G  T  C  G  G  A  T  G  A  T  -3′) and 3′CD3δcDNA-
(5′-C  T  T  G  T  T  C  C  G  A  G  C  C  C  A  G  -3′) specifi  c primers. Plates were stored on 
ice until reverse transcription at 42°C for 1 h followed by a 10 min step at 
94°C. Subsequently, 2.5 μl of cDNA or fi  rst PCR product were used to 
amplify transcripts by two steps of PCR in a fi  nal volume of 32.5 μl. In 
the fi  rst round, multiplex PCR reaction was performed using 0.4 μM of 
each following oligonucleotide: 5′FoxP3-ext (5′-T  T  C  A  T  G  C  A  C  C  A  G  C  T-
C  T  C  A  A  C  G  -3′), 3′FoxP3-ext (5′-C  T  T  C  T  C  C  A  G  C  A  C  C  A  G  C  T  G  C  T  G  -
3′), 5′CD3δ-ext (5′-G  G  G  A  A  C  G  G  T  G  G  G  A  A  C  A  C  T  G  C  -3′), 3′CD3δ-ext 
(5′-A  A  A  G  C  A  A  G  G  A  G  C  A  G  A  G  T  G  G  C  -3′). Reactions were subjected after 
5 min at 94°C to 8 cycles (94°C for 30 s, 60°C for 40 s, 72°C for 50 s), 32 
cycles (94°C for 30 s, 55°C for 40 s, 72°C for 50 s), and a fi  nal elongation 
at 72°C for 5 min. In a second PCR round, each gene was amplifi  ed sepa-
rately using nested primers 5′FoxP3-int (5′-G  G  C  C  T  C  C  C  A  C  C  T  G  G  G  A  T-
C  A  A  C  -3′) and 3′FoxP3-int (5′-C  G  C  C  T  G  G  C  A  G  T  G  C  T  T  G  A  G  G  A  A  -3′) 
or 5′CD3δ-int (5′-G  A  C  T  G  G  A  C  C  T  G  G  G  A  A  A  A  C  G  C  -3′) and 3′CD3δ-
int (5′-C  A  A  T  G  A  T  G  C  C  A  G  C  C  A  C  G  G  T  G  -3′). PCR was performed as in 
the fi  rst step. Reaction products were visualized by electrophoresis on a 2% 
agarose gel.
Statistical analysis. Comparisons between active and inactive sarcoidosis 
patients and control subjects were made using the nonparametric Mann-
Whitney U test. Comparisons of the rate of circulating CD25bright CD4+ 
T cells variation during the evolution of the disease within the same individ-
uals were made using the Wilcoxon Signed Rank test (54). p-values <0.05 
were considered signifi  cant. Statistical analyses were performed with  Statview 
5.0 software (SAS Institute).
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